Which diabetes drug protects the heart better? large study aims to find out

NCT ID NCT06980623

Ongoing Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large study compares two popular diabetes drugs, tirzepatide and semaglutide, in 26,000 people who have both type 2 diabetes and a type of heart failure. Researchers will track who ends up in the hospital for heart failure or dies, to see if one drug works better. The goal is to help doctors choose the best treatment for patients with these two conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide and semaglutide
What this could lead to: If this study shows one drug is clearly better, it could guide doctors to prescribe the more effective option for patients with both diabetes and heart failure.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It also does not test a new drug, just compares existing ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder diastolic heart failure heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE TYPE 2 DIABETES

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.